Evicenter
P&T meetings

Tovecimig (CTX-009)

Second-line advanced biliary tract cancer

Also known as ABL001
Last updated
89 sources

Economic information and modeling reportBudget impact model

Epidemiology and eligible population inputs

5 evidence topics · 7 sources

Budget impact model of tovecimig: eligible population inputs

No evidence found.

Company estimate of the United States population eligible for tovecimig

“Over 15K patients/yr potentially eligible for” (opens the source at this quote in a new tab)

“>26,500 1,2 patients diagnosed with BTC (growing to ~34K by 2037) >24,000 patients Receive 1L treatment (10% resection and 5% cure) >17,000 patients Receive 2L treatment (70% of1L patients)” (opens the source at this quote in a new tab)

“>15,000 patients Eligible for” (opens the source at this quote in a new tab)

“High Volume BTC Accounts BTC Accounts with 50+ Patients” (opens the source at this quote in a new tab)

“BTC is estimated to affect approximately 26,500 patients annually in the United States.” (opens the source at this quote in a new tab)

Market-research estimate of incident biliary tract cancer cases in the United States and the seven major markets

“In 2024, the total number of BTC incident cases across the 7MM was approximately 65,000, and this burden is projected to increase over the forecast period.” (opens the source at this quote in a new tab)

“The US accounted for approximately 19K biliary tract cancer cases in 2024, which are further expected to increase by 2034.” (opens the source at this quote in a new tab)

Share of patients with advanced biliary tract cancer who reach second-line therapy in United States claims data

“Of 413 patients, 84.5% received gemcitabine-based first-line (1L) treatment, 46% received second-line treatment, and 16.5% received third-line (3L) treatment.” (opens the source at this quote in a new tab)

“A total of 514 patients (39.6%) died during the follow-up period without receiving a second-line therapy.” (opens the source at this quote in a new tab)

Share of the second-line population without an actionable mutation addressed by an approved targeted therapy

“The only FDA approved therapies for second line treatment of BTC are targeted therapies that address specific tumor mutations or solid tumors that are microsatellite instability high.” (opens the source at this quote in a new tab)

“We believe that the combination of all targeted therapies are appropriately 10-15% of patients with BTC.” (opens the source at this quote in a new tab)

“For the vast majority of patients with BTC whose tumors do not harbor an actionable mutation with an approved targeted therapy, there is currently no FDA-approved treatment in the second line setting.” (opens the source at this quote in a new tab)

“Biomarker - targeted therapies (e.g. FGFR, IDH1, HER2) offer limited benefit and only applicable to 15 - 20% of patients” (opens the source at this quote in a new tab)

Eligible population sizing for a biomarker-selected second-line comparator in England

“HER2 alterations are identified in about 5% to 10% of cholangiocarcinomas and up to 20% of gallbladder cancers.” (opens the source at this quote in a new tab)

“The committee also noted that the eligible population for zanidatamab was small.” (opens the source at this quote in a new tab)